Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis - Results of a field study

Hepato-Gastroenterology

Volumn 53, Issue 69, 2006, Pages 317-321

  Singer, Manfred V ^a,c   Schmausser H ^b   Schonfeld G ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

5 aminosalicylic acid (5 ASA); Dipentum ; Inflammatory bowel disease (IBD); Olsalazine; Ulcerative colitis

Indexed keywords

OLSALAZINE;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANAMNESIS; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADULT; AGED; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 33745443041     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rao SS, Holdsworth CD, Read NW: Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988; 29:342-345.
2. Kuhbacher T, Schreiber S, Folsch UR: Ulcerative colitis: conservative management and long-term effects. Langenbecks Arch Surg 2004; DOI 10.1007/s00423-004-0477-8.
3. Timmer A, Goebell H: Incidence of ulcerative colitis. 1980-1995 - a prospective study in an urban population in Germany. Z Gastroenterol 1999; 37:1079-1084.
4. Davidson A, Diamond B: Autoimmune diseases. N Engl J Med 2001; 345:340-350.
5. Satsangi J, Morecroft J, Shah NB, et al: Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Gastroenterol 2003; 17:3-18.
6. Ott SJ, Musfeldt M, Wenderoth DF, et al: Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53:685-693.
7. Van Nuenen MH, Venema K, van der Woude JC, et al: The metabolic activity of fecal microbiota from healthy individuals and patients with inflammatory bowel disease. Dig Dis Sei 2004; 49:485-491.
8. Swidsinski A, Ladhoff A, Pernthaler A, et al: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122:44-54.
9. Podolsky D: Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
10. Stange EF: Evidence-based guideline for the diagnosis and treatment of ulcerative colitis. Z Arztl Fortbild Qualitätssich 2002; 96:239-242.
11. Gionchetti P, Rizzello F, Habal F, et al: Standard treatment of ulcerative colitis. Dig Dis 2003; 21:157-167.
12. Kamm MA: Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 2002; 16(Suppl 4):21-24.
13. Campbell DE, Berglindh T: Pharmacology of olsalazine. Scand J Gastroenterol Suppl 1988; 148:7-12.
14. Stoa-Birket vedt G, Florholmen J: The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Aliment Pharmacol Ther 1999; 13:357-361.
15. Mahmud N, O'Toole D, O'Hare N, et al: Evaluation of renal function following treatment with 5-aminosalicylic acid derivates in patients with ulcerative colitis. Aliment Pharmacol Ther 2002; 16:207-215.
16. Gionchetti P, Campieri M, Venturi A, et al: Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Aliment Pharmacol Ther 1996; 10:601-605.
17. Ewe K, Becker K, Ueberschaer B: Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. Z Gastroenterol 1996; 34:225-229.
18. Staerk Laursen L, Stokholm M, Bukhave K, et al: Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31:1271-1276.
19. Lauritsen K: Olsalazine is associated with lower systemic exposure to 5-aminosalicylic acid (5-ASA) than mesalazine: a meta-analysis of five independent studies. Gastroenterology 1995; 108(Suppl 4):A859.
20. Ryde EM, Ahnfelt NO: The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur J Clin Pharmacol 1988; 34:481-488.
21. Sandberg-Gertzén H, Ryde M, Jarnerot G: Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 1983; 18:107-111.
22. Jarnerot G: Clinical tolerance of olsalazine. Scand J Gastroenterol Suppl 1988; 23:21-23.
23. Kruis W, Brandes JW, Schreiber S, et al: Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12:707-715.
24. Rao SS, Dundas SA, Holdsworth CD, et al: Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 1989; 30:675-679.
25. Nilsson A, Danielsson A, Lofberg R, et al: Olsalazine versus sulphalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 1995; 90:381-387.
26. Courtney MG, Nunes DP, Bergin CF, et ai: Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992; 339:1279-1281.
27. Greenberg RN: Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6:592-599.